ATLANTA– Southeast BIO (SEBIO) named four winners of the First Annual SEBIO Awards in a ceremony held at its Ninth Annual Investor Forum in Pinehurst, NC earlier this month. (more…)
By Allan Maurer, Tech Journal South
GAINSVILLE, FL—Transgeneron Therapeutics, winner of the Southeast BIO investor forum early-stage shootout competition in early November, is developing a “master switch” protein that reverses diabetes in mice and may do the same in humans. (more…)
By Allan Maurer, Tech Journal South
Atlanta, GA—Visioneering, which developed a patented, FDA-approved technology for presbyopia, the aging eye’s loss of the ability to read or focus close-up, says its presentation at SEBIO’s investor forum early in November stirred up serious investor interest. (more…)
Atlanta, GA— Southeast BIO (SEBIO) announced four winners of the First Annual SEBIO Awards in a ceremony held at its Ninth Annual Investor Forum in Pinehurst, NC on November 8th. The awards honored companies in the following categories: Southeast (SE) Deal of the Year: Initial Funding; SE Deal of the Year: Venture Capital Transaction and SE Deal of the Year: Strategic Transaction. In addition, the organization awarded its inaugural SE Leadership Award to an individual or organization that made a notable contribution to the growth of the life sciences industry in the region over the last year. The winners were Argolyn Bioscience, Inc., Metastatix, Inc, Targacept, Inc., and Aaron Davidson of HIG Ventures, respectively. (more…)
Vienna, VA, Karmiel, Israel and London, UK – 29 November, 2007 – Medgenics, Inc., a US biopharmaceutical company with key operations in Israel, is pleased to announce that it has raised £3.28 million in its Initial Public Offering (“IPO”) in connection with its forthcoming Admission to the AIM market of the London Stock Exchange, expected on 4 December 2007. The shares being placed in the IPO are being issued at 10 pence per share, giving the Company a market capitalisation of approximately £10.4 million immediately after the IPO (£27.6 million on a fully diluted basis, equivalent to ca $58m). (more…)
Daytona Beach, FL—ForHealth Technologies has closed on a total of $9 million of new capital financing. The round consisted of a $4 million equity component and an additional $5 million of debt financing. (more…)
Atlanta, GA- Southeast BIO (SEBIO), a regional nonprofit organization dedicated to fostering the growth of the Southeast’s life sciences industry, has announced the winner of its first annual BIO/Plan Competition, a year long business creation competition. The winner is Triptcor Pharmaceuticals, a pre-incorporated technology to be spun-out of Emory University. Triptcor will take home the $100,000.00 (non-dilutive) BIO/Plan 1st prize. (more…)
Atlanta, GA– More than 400 people attended the Ninth Annual Southeastern BIO Investor Forum on November 7th-8th in Pinehurst, North Carolina. The Forum is the Southeast’s premier life sciences venture capital conference. (more…)
Atlanta, Ga and Paris, France—Orthopedic imaging company biospace med has closed an $18 million venture financing led by NBGI Ventures of London, and Credit Agricole Private Equity, Edmond de Rothschild Investment Partners and UFGPE, all of Paris. Current investors also participated. (more…)
TechJournal South selected 25 of most influential people in the Southeast technology and entrepreneurial space from nominations by venture capitalists, serial entrepreneurs, and tech related organizations in its Nov. print edition. We’ll be running a selection of them daily for the next few weeks. Today: Rebecca Kaufman, chair of SEBIO, and attorney with King & Spalding in Atlanta.
Rebecca Kaufman combines legal and biotech expertise
By Allan Maurer, Tech Journal South
ATLANTA, GA—Rebecca Kaufman recalls working as a college intern as a researcher at the National Cancer Institute when Robert Gallo, the U.S. discoverer of the AIDS virus got into a fight with a French researcher over patent rights to HIV. Kaufman, a counsel with King & Spalding’s Intellectual Practice Group in Atlanta and chairman of SEBIO, says, “I found the patent battle so much more interesting than what I was doing at the bench as a researcher.” (more…)
